Med. J. Cairo Univ., Vol. 88, No. 3, June: 1247-1255, 2020
www.medicaljournalofcairouniversity.net
Comparison between Different Risk Scores in Predicting Hospital
Mortality for Patients with Decompensated Liver Cirrhosis: A Single
Center Study
MAHMOUD H. ALLAM, M.D.*; MOHAMED A.S. KOHLA, M.D.* and WESAM S. MORAD, M.D.**
The Departments of Hepatology & Gastroenterology* and Epidemiology & Preventive Medicine**,
National Liver Institute, Menoufia University, Shebin El-Kom, Egypt
Abstract
Key Words: Decompensated cirrhosis – Predictor scores –
Survival – HCV.
Background: Predicting prognosis of patients with decompensated liver cirrhosis remains an important issue.
Aim of Study: This study aimed to evaluate the predictive
value of different patients' characteristics and risk scores as
regard patients' outcome (death or survival).
Patients and Methods: 672 patients with different complications of cirrhosis (gastrointestinal bleeding, hepatic
encephalopathy, SBP, HRS and ascites) who were admitted
to the National Liver Institute Hospital between 2015 and
2018 were included in this study. On admission to the hospital,
assessment of patients by routine laboratory work-up (liver
and kidney function tests and complete blood count), ultrasound
of the abdomen, upper endoscopy for those with bleeding and
ascitic fluid sampling for those with ascites. MELD, MELDNa, CTP, ALBI and PALBI grades were calculated for all
patients. At the end of hospitalization, patients outcomes were
stratified as survived or died. Patients clinical and laboratory
parameters were correlated with hospital mortality. Receiver
Operating Curves (ROC) for risk scores were plotted to
discriminate the predictive power of risk scores versus mortality.
Results: The overall hospital mortality was 27.1%. Univariate analysis revealed age, total and direct bilirubin, albumin,
transaminases, alkaline phosphatase, INR, serum creatinine,
BUN, serum sodium and white cells count as significant,
while multivariate analysis concluded age, total bilirubin,
serum creatinine, Blood Urea Nitrogen (BUN), serum sodium
(Na), INR and white blood cells count significance with
hospital mortality, (p<0.05). The area under receiver operating
curve for MELD-Na was (0.85), MELD score (0.84), CTP
score (0.82), AlBI grade (0.75) and PALBI grade (0.75),
p <0.001.
Conclusion: MELD-Na and MELD scores are good predictors for prognosis of patients with decompensated liver
cirrhosis. But, ALBI and PALBI grade are promising scores
which needs more validation.
Correspondence to: Dr. Wesam S. Morad,
E-Mail: wesammorad@gmail.com
Introduction
LIVER cirrhosis is one of the leading causes of
morbidity and mortality worldwide and the second
cause of digestive disease mortality [1] . It accounts
for about 40,000 deaths per year in the United
States and about 170,000 deaths per year in Europe
where 20 million people suffer of chronic liver
diseases [2-4] . The annual rate of liver decompensation is estimated to be about 11% per year which
reduces expected patients' survival to 81.8% and
50.8% at 1 & 5 years respectively [1,5,6] .
Over time, there was many attempts to develop
simple, accurate and objective scoring systems
which can predict prognosis of patients with cirrhosis on basis of their clinical and laboratory data
[ 7] .
The Child-Pugh (CTP) score is one of the oldest
scores that's widely used to determine prognosis
of patients with liver cirrhosis. But, its accuracy
is influenced by subjectivity of hepatic encephalopathy and ascites as variables used for its calculation [8,9] .
Abbreviations:
HCV : Hepatitis C.
MELD : Model for End Stage Liver Disease.
ROC : Receiver Operating Curve.
UGIB : Upper Gastrointestinal Bleeding.
HE
: Hepatic Encephalopathy.
HRS : Hepatorenal Syndrome.
SBP : Spontaneous Bacterial Peritonitis.
1247
1248
Different Risk Scores Predicting Mortality of Decompensated Liver Cirrhosis Patients
The Model for End-Stage Liver Disease
(MELD) had been developed to estimate survival
of patients undergoing trans-jugular intrahepatic
Porto-systemic shunts and then was generalized
to patients with different etiologies and severity
of liver diseases [10] . It was assumed that MELD
score is better than CTP score on prediction of
waiting-list mortality before liver transplantation
Patients and Methods
This retrospective single center study was conducted between 2015 and 2018 on all patients
admitted to the ward of Hepatology and Gastroenterology Department of the National Liver Institute,
Menofia University, Egypt with complications of
end stage liver diseases.
[11].
However, mortality still occurs in about 20%
of patients with low MELD score as it was mainly
designed for patients with end-stage liver cirrhosis
The study started after its approval by the
institution review board of the National Liver
Institute and obtaining and informed consent from
patients enrolled in this study.
[12].
Other limitations of MELD score was that
important complications which may contribute to
poor prognosis like ascites and hyponatremia are
not included in MELD score. So, many trials were
done to modify MELD score in order to improve
its predictive accuracy [12,13] .
Recently, MELD-Sodium score (MELD-Na)
score has been developed to provide better prediction of mortality among patients on the waiting
list for liver transplantation (TX) [14,15] .
More recently, a new score has been developed
to predict survival in patients with Hepatocellular
Carcinoma (HCC) based on two variables: Serum
albumin and total bilirubin. This score is called
the Albumin-Bilirubin (ALBI) grade, a simple
score calculated from 2 objective variables which
are easily measured and routinely requested for
such patients [16] .
ALBI grade had significant predictive value
for the long-term prognosis of patients with HBVrelated cirrhosis (compensated and decompensated
with better accuracy than CTP and MELD scores
[17] . Moreover, ALBI was used evaluate survival
in patients with decompensated cirrhosis receiving
Direct Acting Antiviral (DAA) therapy in a study
published as an abstract [18] .
PALBI model was developed by incorporating
platelet count into ALBI grade and was proposed
to have better value in evaluating patient's survival
with HCC [19] and recently has been used as a
predictor of survival in patients with complications
of liver cirrhosis [20] .
Aim of the study:
To evaluate the predictive value of different
patients' characteristics and risk scores as regard
patients' outcome (death or survival).
Patients' selection:
Patients with decompensated liver cirrhosis due
to chronic Hepatitis C (HCV) infection were included in this study. The diagnosis of HCV infection
based on sero-positivity of its antibodies or detection of any level of HCV viremia by Polymerase
Chain Reaction (PCR) test.
The diagnosis of liver cirrhosis depended on
presence clinical features of liver cirrhosis (e.g.
history of liver disease, imaging features of cirrhosis, endoscopic findings of portal hypertension or
patients' laboratory data). Liver decompensation
was considered when patients presented with ascites, variceal bleeding, hepatic encephalopathy
or non-obstructive hepatocellular jaundice.
Patients were enrolled in this study at time of
their admission to hospital with one or more of the
following complications:
I- Upper Gastro-Esophageal Bleeding (UGIB):
When they presented with hematemesis and/or
melena with presence of esophageal with/out gastric
varices on upper endoscopy.
II- Hepatic encephalopathy based on clinical
judgment and classified according to West-Haven
criteria.
III- Spontaneous Bacterial Peritonitis (SBP)
based on counting of ascitic fluid leucocytes' count
(<250 neutrophils/mm 3 and culture result of ascitic
samples.
IV- Hepatorenal Syndrome (HRS): In those
with progressive increase of serum creatinine even
after stopping of diuretics and plasma volume
expansion by infusion of human albumin at dose
(1gm./kg) for 2 days.
V- Ascites: With different degrees with absence
of any of previously mentioned complications.
Mahmoud H. Allam, et al.
Exclusion criteria:
We excluded patients with liver diseases due
to other etiologies e.g. chronic HBV, auto-immune
or cholestatic liver diseases and alcoholic patients.
We also excluded patients with acute liver failure,
septic shock, those with hepatocellular carcinoma
or other extra-hepatic malignancies and those <18
years old.
Baseline assessment of the patients:
On admission, patients' demographics were
recorded including age, gender, etiology and duration of liver disease, other co-morbidities specially
diabetes mellitus, history of previous admissions
and previous similar attacks of the same presenting
complication.
Routine laboratory work-up was done including
liver function tests (serum albumin, bilirubin,
transaminases [aspartate & alanine], alkaline phosphatase, INR and total protein levels), kidney
function tests (serum creatinine, blood urea and
serum sodium and potassium levels) and complete
blood count (hemoglobin, white blood cells and
platelets count).
Imaging study was done by routine ultrasound
examination of the abdomen and dynamic computed
tomography was requested on detecting any suspicious liver lesion. Upper endoscopy was done
according to standard protocol for patients with
upper gastro-esophageal bleeding. Therapeutic
variceal band ligation was done for those with
bleeding esophageal varices and sclerotherapy with
tissue adhesives was done for bleeding gastric
varices. Patients with refractory bleeding were
referred for either Tran-sjagular Intrahepatic Portosystemic Shunt (TIPS) or underwent devascularization surgery. Ascitic fluid sampling was
done under complete sterile conditions for those
with ascites. Counting of total leucocytes and
neutrophils and culture of these samples was done.
Evaluation for liver transplantation started for
all patients according to the standard protocol of
pre-transplant assessment in our institute. But, as
Living Donor Liver Transplant (LDLT) is the only
available type of liver transplantation in Egypt,
many patients died during their evaluation for
LDLT mostly due to scarcity of suitable donor.
Study design:
During admission, patients were treated according to the standard protocol for each complication
which could be modified according to patients'
response. The final outcome was stratified as survived or died at the end of their hospital admissions
1249
and this was considered as the dependent variable
to be evaluated by this study.
In order to predict patients' mortality during
hospitalization, different scores were calculated
according to their known equations by using patients' data. MELD score was calculated according
to the standard formula as 3.78 X LN (bilirubin
[mg/dL]) + 9.57 X LN (creatinine [mg/dL]) + 11.20
X LN (international normalized ratio) + 6.43 [10] .
Minimal value for MELD score was 1 and maximal
value for creatinine was 4. Creatinine was set at 4
if the patient was receiving renal replacement
therapy.
The MELD-Na score was calculated as MELD
+ (140 – Na [mmol/L]) – 0.025 X MELD X (140
– Na [mmol/L]) [14] . The Na concentration is bound
between 125 and 140mmol/L. The conventional
CTP score was calculated on the basis of serum
bilirubin and albumin levels, the prothrombin time,
as well as the presence and severity of ascites and
encephalopathy [8] .
The ALBI grade was calculated as follows:
[(Log10 bilirubin X 0.66) + (albumin X [–0.085]),
where bilirubin is in µ
mol/L and albumin in g/L]
[16] .
Accordingly, PALBI grade was calculated as
the following equation: 2.02 X log10 bilirubin –
0.37 X (log10 bilirubin) 2 – 0.04 X albumin – 3.48
X log10 platelets + 1.01 X (log10 platelets) 2 ,
mol/L, albumin in g/L
bilirubin was expressed in µ
L [19] .
and blood platelet count in 1000/ µ
Statistical analysis:
Continuous variables were presented as mean
± standard deviation and Categorical variables
were expressed as frequencies or percentages.
Comparisons of variables were performed using
Student's t for continuous variables and chi-square
test for categorical variables. Multivariable Cox's
proportional hazard model was carried out to identify independent factors associated with the outcome (death or survival). Factors with p<0.05 in
the univariate cox regression analysis were entered
into the multivariable model.
The discriminative ability of all studied prognostic scores to predict the outcome of patients
with decompensated cirrhosis was evaluated by
using the area under the receiver operating characteristic curve (ROC). This has the true-positive
and false-positive rates on the vertical and horizontal axes, respectively. When the AUC approaches 1.0, the model approaches 100% sensitivity and
1250
Different Risk Scores Predicting Mortality of Decompensated Liver Cirrhosis Patients
specificity. p-value <0.05 was considered statistically significant. Statistical analysis was conducted
by SPSS (version 23.0 IBM).
Results
This study was conducted on 672 patients admitted to hospital with complications of end stage
decompensated liver cirrhosis attributed to chronic
HCV infection. Among these patients, 182 patients
died during their hospital stay with overall hospital
mortality rate of (27%).
Table (1), shows demographics of studied patients at time of their admissions and their relation
to patient's survival or death on univariate analysis.
Three hundred and fourteen patients presented
with upper gastrointestinal bleeding of them 69
patients (22%) died during their hospitalization.
Also, 295 patients presented with hepatic encephalopathy either alone or with other complications
(47.8% mortality), 246 patients had SBP (40.2%
mortality) and 489 patients presented had ascites
(34.7% mortality) during hospitalization.
Univariate analysis of different laboratory parameters and their relation with patient's survival
revealed that many variables (patients' age, serum
total and direct bilirubin, albumin, transaminases,
alkaline phosphatase, INR, serum creatinine, BUN,
serum Na and white cells count) were significant
with mortality (p<0.05), Tables (1,2).
Table (1): Patients' demographics on admission to hospital and its significance with hospital
mortality.
Total
N. (%)
Survived
N. (%)
Died
N. (%)
Gender:
Male
Female
517 (76.9)
155 (23.1)
369 (71.4)
121 (78.1)
148 (28.6)
34 (21.9)
0.100
UGIB on admission
314 (46.7)
245 (78)
69 (22)
0.000**
Frequency of UGIB attacks:
First attack
Recurrent attack
142 (45)
172 (55)
105 (73.9)
140 (81.4)
37 (26.1)
32 (18.6)
0.007**
Size of esophageal varices:
Small
Large
84 (27)
230 (73)
68 (80.9)
177 (76.9)
16 (19.1)
53 (23.1)
0.016*
Presence of gastric varices
120 (38)
108 (90)
12 (10)
0.000**
Hepatic encephalopathy on admission:
Yes
No
295 (43.9)
377 (56.1)
154 (52.2)
336 (68.5)
141 (47.8)
41 (22.5)
0.000**
Grade of HE:
Mild grades
Severe grades
71 (34.6)
134 (65.4)
50 (70.4)
69 (51.5)
21 (29.6)
65 (48.5)
0.000**
Diagnosis of SBP on admission:
Yes
No
246 (36.6)
426 (63.4)
147 (59.8)
343 (80.5)
99 (40.2)
83 (19.5)
0.120
Presence of ascites on admission:
Yes
No
498 (74.1)
174 (25.9)
325 (65.3)
165 (94.8)
173 (34.7)
9 (5.2)
0.012*
Hepatorenal syndrome
171 (25.4)
87 (50.8)
84 (49.1)
0.023*
Ascites degree:
Mild ascites
Moderate ascites
Marked ascites
85 (12.6)
320 (47.6)
93 (13.8)
67 (78.8)
198 (61.9)
60 (64.5)
18 (21.2)
122 (38.1)
33 (35.5)
0.000**
CTP score grade:
A
B
C
52 (7.7)
116 (17.3)
504 (75.0)
51 (98.1)
110 (94.8)
329 (65.3)
1 (1.9)
6 (5.2)
175 (34.7)
0.000**
Total
672 (100)
490 (72.9)
182 (27.1)
Variables (N)
pvalue
1251
Mahmoud H. Allam, et al.
Table (2): Clinical and laboratory characteristics of studied patients and comparison between
different risk scores.
Variable
Age
MELD score
CTP score
MELD-Na score
ALBI score
PALBI score
Duration of hospital stay
Total bilirubin
Direct bilirubin
Total protein
Albumin
AST
ALT
Alkaline phosphatase
GGT
INR
BUN
Creatinine
Na
K
Hemoglobin
WBCs
Platelet count
Total (N=672)
Mean ± SD (range)
Survived
(N=490)
Mean ± SD
Died
(N=182)
Mean ± SD
pvalue
52.2± 10.3 (17-82)
19.2±7.9 (6-48)
11.2±2.7 (5-15)
23.7±8.4 (6-50 )
–1.4±0.8 (–3.4-0.6)
–2.2±0.8 (–4.8-0.2)
7.3±5.3 (1-48)
5.6±7.9 (0.2-57)
3.3±5.6 (0.1-38)
6.2± 1.1 (3-10)
2.3±0.6 (1-7.6)
95.8±366.4 (2-6697)
66.4± 144.3 (2-2945)
109.9±78.4 (2-957)
53.3 ±65.5 (1-978)
1.9±0.79 (1-9.53)
75.0±57.7 (4-397)
1.4± 1.1 (0-15.4)
130.2±7.7 (93-145)
5.1 ± 8.1 (2-9.8)
10.0±2.2 (3-19)
10.1 ±7.2 (1.4-69)
113.3±80.9 (6-652)
51.6± 10
16.7±5.6
10.5±2.5
20.9±6.8
–1.5±0.6
–2.4±0.7
7.2 ±5
3.7±5.3
1.9±3.8
6.2± 1.1
2.4±0.6
63.5±70.2
49.4±43.6
100±55.4
52.6±67.8
1.7±0.5
57.9±35.1
1.1 ±0.5
132.2±6.3
4.8±3.5
9.9±2.1
8.8±5.9
112.6±84.3
53.7± 10.9
26.9± 8.5
13.2± 1.8
31.7±7.4
–0.9±0.8
–1.7±0.8
7.5±5.8
10.7± 109
6.9±7.7
6.1 ± 1.1
2.0±0.5
182.9±688.3
112.1 ±262.9
136.6± 116.2
55.1 ±58.9
2.3 ± 1.2
121.3 ±77.9
2.1 ± 1.7
125± 8.8
5.9± 14.4
10.3±2.5
13.5± 8.9
115.1 ±71.6
0.022*
0.000**
0.000**
0.000**
0.000**
0.000**
0.451
0.000**
0.000**
0.063
0.000**
0.021*
0.002**
0.000**
0.637
0.000**
0.000**
0.000**
0.000**
0.311
0.057
0.000**
0.704
than MELD score in predicting patient's mortality,
Table (3) and Fig. (2).
Multivariate analysis for these significant variables revealed that age, total bilirubin, serum
creatinine, blood urea nitrogen (BUN), serum
sodium (Na), INR and white blood cells count
were statistically significant with hospital mortality,
(p<0.05).
The distribution of studied patients at different
MELD score's categories is shown in Fig. (1).
Patients were stratified into 6 categories according
to their MELD scores: <10, 10-14, 15-19, 20-24,
25-35 and >35. The mean value of MELD score
was 19.2 ±7.9 for all studied patients, while mean
MELD was different between patients who survived
than those who died (16.7 ± 5.6 and 26.9± 8.5 respectively). The hospital mortality increased significantly across different MELD score categories
with 70 patients (84.3%) with MELD score >35
died during hospitalization, (p<0.001), Table (2)
and Fig. (1).
On comparing different scores as regard their
discriminative abilities of predicting patient's mortality, MELD, MELD-Na and CTP score had better
Area Under Receiver Operating Curve (AUROC)
than AlBI and PALBI grades (AUROC >0.8).
MELD-Na had slightly better AUROC than MELD
score (0.85 vs. 0.84).
PALBI and ALBI scores had similar AUROC
but PALBI score had better accuracy even more
Table (3): Comparison between ROC characteristics as regard prediction of hospital mortality.
Sensitivity
%
Specificity
%
Odds
ratio%
Risk
ratio%
PPV
%
NPV
%
16
83
69
19.06
4.91
78
84
83
11
80
67
11.65
4.26
69
84
80.8
26
–1.5
97
73
9.8
5.1
77
86
80.0
0.75
91
78
7.73
1.9
68
67
79
0.75
–2.5
91
84
7.87
1.99
57
89
88
Score
AUC
MELD score
0.84
CTP score
0.82
MELD-Na
0.85
ALBI grade
PALBI grade
Cut off
level
Accuracy
%
1252
Different Risk Scores Predicting Mortality of Decompensated Liver Cirrhosis Patients
Distribution of patients at different
MELD score categories (n=672)
and risk scores as regard patients' outcome (death
or survival).
200
Over time, there was many attempts to develop
a classification system which can characterize the
degree of liver injury and predict prognosis of
patients with liver cirrhosis using objective clinical
and laboratory variables [7] .
Number
150
100
MELD and CTP scores are the main scores
used for the prediction of prognosis of patients
with liver cirrhosis. Peng et al, reviewed the diagnostic accuracy of MELD and CTP scores in a
large meta-analysis and concluded that there's a
need to develop a new score that can precisely
predict prognosis of patients with liver cirrhosis
[21] .
50
0
<10
10-14 15-19 20-24 25-35 >35
MELD score category
Survived
MELD category
N (%)
Survived
Died
<10
died
10-14 15-19 20-24 25-35
46
(95.8)
2
(4.2)
142
(92.8)
11
(7.2)
102
(72.9)
38
(27.1)
158
(87.8)
22
(12.2)
29
(42.6)
39
(57.4)
>35
13
(15.7)
70
(84.3)
Fig. (1): Distribution of studied patients at different MELD
score categories.
ROC Curve
1.0
Sensitivity
0.8
Studies had validated this new score in assessment of prognosis and defining management of
patients with HCC [23-26] . Subsequently, studies
validated ALBI grade for patients with chronic
liver diseases in a study conducted on patients with
upper gastrointestinal bleeding [27] .
PALBI grade was developed in 2015 by Sasan,
et al. [19] by incorporation of platelet count into
ALBI grade to predict prognosis of patients with
HCC undergoing curative interventions. Later on,
it was validated on patients presented with complications of liver cirrhosis [28] .
0.6
0.4
0.2
0.0
0.0
Accordingly, MELD score was modified by
adding serum sodium to its variables [14,15] . More
recently, Johnson, et al., created a novel score, the
ALBI grade, using only two biochemical parameters, serum albumin and total bilirubin levels. This
was initially developed to assess liver condition
in patients with HCC.
0.2
0.4
0.6
1-Specificity
0.8
1.0
Source of the Curve
MELD
ALBI
MELD Na
PALBI
CTP scor
Reference Line
In this study, we aimed to evaluate predictors
of prognosis of patients presented with complications of decompensated liver cirrhosis secondary
to HCV infection.
Discussion
The presence of such complications itself and
frequency of its attacks were significant with
hospital mortality. This agreed with many studies
which confirmed that presence of such complications (e.g. UGIB, HE, SBP, HRS and ascites) is
associated with increased mortality of such patients
[2,29,30] .
In this study, we evaluated 672 patients with
decompensated liver cirrhosis due to HCV infection
presented with different complications (gastrointestinal bleeding, hepatic encephalopathy, SBP,
HRS and ascites) in order to evaluate the predictive
capabilities of different patients' characteristics
On correlating individual patients clinical and
laboratory variables with mortality, patient's age,
serum total and direct bilirubin, albumin, transaminases, alkaline phosphatase, INR, serum creatinine,
BUN, serum Na and white cells count were significant with mortality, (p<0.05). This agrees with
Fig. (2): ROCs of different scores as regard hospital mortality.
1253
Mahmoud H. Allam, et al.
many studies assuming that deterioration of liver
and kidney functions and hyponatremia are strongly
associated with mortality in patients with end stage
liver disease [31-33] .
To evaluate the predictive power of different
scores on predicting prognosis of patients with
complicated liver cirrhosis, univariate analysis
showed strong statistical significance of MELD,
MELD-Na, CTP scores, ALBI and PALBI grades
with hospital mortality of these patients ( p<0.001).
So, for further comparison of discriminative
power of these scores, ROCs of these scores were
plotted and their AUROC, sensitivity, specificity
and accuracy were calculated.
The AUROC versus the hospital mortality for
these scores was not much different between the
MELD (AUC: 0.84) vs. MELD-Na (AUC: 0.85),
or CTP score (AUC: 0.82). But, this was higher
than ALBI (AUC: 0.75) and PALBI grades (AUC:
0.75). But, PALBI grade had better accuracy in
predicting mortality (88%).
This was different from another study when
ALBI grade was evaluated in 626 patients with
decompensated cirrhosis due to HCV during DAA
therapy and it was assumed that ALBI grade may
be an independent risk factor for clinical deterioration and death [18] .
In a study by Oikonomou et al., ALBI grade
was evaluated prospectively in a large cohort of
patients with stable decompensated cirrhosis of
different etiology. They assumed that ALBI grade
had discriminative ability (AUC: 0.695), better
than CTP score (AUC: 0.611) and rather comparable to that of MELD score (AUC: 0.72), regarding
the long-term outcome (death or LT) [34] .
They also examined PALBI on a cohort of 325
stable decompensated patients which revealed that
PALBI was an important risk factor (HR: 2.06,
95% CI [1.47-2.9], p<0.001) associated with patients' outcome [34] .
When PALBI grade was validated by Liu et al.,
it had good prognostic power in differentiating
patients' survival (higher AUC values compared
with MELD, CTP, and ALBI grade, all p<0.05)
[28] .
disease had increased serum creatinine which
increased the predictive power of MELD score
and in addition to low serum sodium which also
affected MELD-Na predictive power. These patients
had ascites, hepatic encephalopathy and coagulopathy which markedly increased CTP score predictive capability for short term mortality.
Patients with MELD score >35 had the worst
survival rate among patients (70 of them died
(84.3%) during hospitalization, p<0.00 1). This was
similar to a study by Ling et al., who found that
patients with MELD >39 before liver transplantation carried the worst survival [35] .
Finally, we confirm there are restrictions of
this study as it is a single center study and patients
due to other etiologies should be included. Also,
ALBI and PALBI grades are valuable scores which
can predict prognosis of patients with decompensated cirrhosis but there's need of further researches
to be confirmed.
Conclusion:
MELD-Na and MELD scores are good predictors for prognosis of patients with decompensated
liver cirrhosis. But, ALBI and PALBI grade are
promising scores which needs more validation.
References
1- JOHNSON K.B., CAMPBELL E.J., CHI H., ZHENG H.,
KING L.Y., WU Y., et al.: Advanced disease, diuretic use,
and marital status predict hospital admissions in an ambulatory cirrhosis cohort. Dig. Dis. Sci., 59: 174-82, 2014.
2- SERAJ S.M., CAMPBELL E.J., ARGYROPOULOS S.K.,
WEGERMANN K., CHUNG R.T. and RICHTER J.M.:
Hospital readmissions in decompensated cirrhotics: Factors
pointing toward a prevention strategy. World J. Gastroenterol., 23: 6868-76, 2017.
3- CHIRAPONGSATHORN S., TALWALKAR J.A. and
KAMATH P.S.: Readmission in cirrhosis: A growing
problem. Curr. Treat. Options. Gastroenterol., 14: 23646, 2016.
4- BLACHIER M., LELEU H., PECK-RADOSAVLJEVIC
M., VALLA D.C. and ROUDOT-THORAVAL F.: The
burden of liver disease in Europe: A review of available
epidemiological data. J. Hepatol., 58: 593-608, 2013.
5- FAYAD L., NARCISO-SCHIAVON J.L., LAZZAROTTO
C., RONSONI M.F., WILDNER L.M., BAZZO M.L., et
al.: The performance of prognostic models as predictors
of mortality in patients with acute decompensation of
cirrhosis. Ann. Hepatol., 14: 83-92, 2015.
In another study, the PALBI had better discriminative ability for short term mortality than CTP
score (AUC: 0.847 vs. 0.672, p<0.001) [20] .
6- PLANAS R., MONTOLIU S., BALLESTE B., RIVERA
M., MIQUEL M., MASNOU H., et al.: Natural history
of patients hospitalized for management of cirrhotic
ascites. Clin. Gastroenterol. Hepatol., 4: 1385-94, 2006.
Our explanation of such result is that these
large number of these patients with end stage liver
7- SCHUPPAN D. and AFDHAL N.H.: Seminar Liver cirrhosis. Lancet, 371: 838-51, 2008.
1254
Different Risk Scores Predicting Mortality of Decompensated Liver Cirrhosis Patients
8- PUGH R., MURRAY-LYON I. and DAWSON J.: Transection of the oesophagus for bleeding oesophageal varices.
Br. J. Surg., 60: 646-9, 1973.
9- DURAND F. and VALLA D.: Assessment of the prognosis
of cirrhosis: Child-Pugh versus MELD. J. Hepatol., 42:
100-7, 2005.
10- KAMATH P.S., WIESNER R.H., MALINCHOC M.,
KREMERS W., THERNEAU T.M., KOSBERG C.L.,
D'AMICO G., et al.: A model to predict survival in patients
with end-stage liver disease. Hepatology, 33: 464-70,
2001.
11- BIGGINS S.W., RODRIGUEZ H.J., BACCHETTI P.,
BASS N.M., ROBERTS J.P. and TERRAULT N.A.: Serum
sodium predicts mortality in patients listed for liver
transplantation. Hepatology, 41: 32-9, 2005.
12- HEUMAN D.M., et al.: Persistent ascites and low serum
sodium identify patients with cirrhosis and low MELD
scores who are at high risk for early death. Hepatology,
40: 802-10, 2004.
13- MYERS R.P., et al.: Validation of the five-variable Model
for End-stage Liver Disease (5vMELD) for prediction of
mortality on the liver transplant waiting list. Liver Int.,
34: 1176-83, 2014.
14- KIM W.R., BIGGINS S.W., KREMERS W.K., WIESNER
R.H., KAMATH P.S., BENSON J.T., EDWARDS E., et
al.: Hyponatremia and mortality among patients on the
liver-transplant waiting list. N. Engl. J. Med., 359: 101826, 2008.
15- VITALE A., BERTACCO A., GAMBATO M., D'AMICO
F., MORALES R.R., FRIGO A.C., ZANUS G., et al.:
Model for end-stage liver disease sodium and survival
benefit in liver transplantation. Transpl. Int., 26: 138-44,
2013.
16- JOHNSON P.J., BERHANE S., KAGEBAYASHI C.,
SATOMURA S., TENG M., REEVES H.L. and
O'BEIRNE J., et al.: Assessment of liver function in
patients with hepatocellular carcinoma: A new evidence
based approach-The ALBI grade. J. Clin. Oncol., 33: 5508, 2015.
17- CHEN R.C., CAI Y.J., WU J.M., WANG X.D., SONG
M., WANG Y.Q., ZHENG M.H., et al.: Usefulness of
albumin-bilirubin grade for evaluation of long-term prognosis for hepatitis B-related cirrhosis. J. Viral. Hepat.,
24: 238-45, 2017.
18- WALKER A.J., JOHNSON P.J. and BERHANE S.: Liver
function as measured by albumin-bilirubin score within
decompensated patients receiving direct acting antiviral
therapy. In: The International Liver Congress 2017. Amsterdam, the Netherlands 19-23 April; 2017.
19- ROAYAIE P.S., JIBARA G., BERHANE S., TABRIZIAN
P., PARK J.W., YANG J., YAN L., et al.: PALBI-An
Objective Score Based on Platelets, Albumin & Bilirubin
Stratifies HCC Patients Undergoing Resection & Ablation
Better than Child's Classification. In AASLD Liver Learning; 2015.
20- ELSHAARAWY O., SAMEA E.A., GOMAA A., ALLAM
N. and SAAD M.: PALBI, The Platelet-Albumin-Bilirubin
score-A better predictor of outcome of Acute Variceal
Bleeding. In: The International Liver Congress 2017.
Amsterdam, the Netherlands 19-23 April, 2017.
21- PENG Y., QI X. and GUO X.: Child-Pugh versus MELD
Score for the Assessment of Prognosis in Liver Cirrhosis.
Medicine (Baltimore), 95: 1-29, 2016.
22- CHAN A.W.H., KUMADA T., TOYODA H., TADA T.,
CHONG C.C.N., MO F.K.F., YEO W., et al.: Integration
of albumin-bilirubin (ALBI) score into Barcelona Clinic
Liver Cancer (BCLC) system for hepatocellular carcinoma.
J. Gastroenterol. Hepatol., 31: 1300-6, 2016.
23- CHAN A.W.H., CHONG C.C.N., MO F.K.F., WONG J.,
YEO W., JOHNSON P.J., YU S., et al.: Incorporating
Albumin-Bilirubin grade into the Cancer of the Liver
Italian Program system for hepatocellular carcinoma. J.
Gastroenterol. Hepatol., 32: 221-8, 2016.
24- KUO Y.H., WANG J.H., HUNG C.H., RAU K.M., WU
I.P., CHEN C.H., KNEE K.M., et al.: The ALBI grade
predicts the prognosis of patients with advanced hepatocellular carcinoma received sorafenib. J. Gastroenterol.
Hepatol., 11, 2017.
25- OGASAWARA S., CHIBA T., OOKA Y., SUZUKI E.,
KANOGAWA N., SAITO T., MOTOYAMA T., et al.:
Liver function assessment according to the AlbuminBilirubin (ALBI) grade in sorafenib-treated patients with
advanced hepatocellular carcinoma. Invest. New Drugs,
33: 1257-62, 2015.
26- ZOU D., QI X., ZHU C., NING Z., HOU F., ZHAO J.,
PENG Y., et al.: Albumin-bilirubin score for predicting
the in-hospital mortality of acute upper gastrointestinal
bleeding in liver cirrhosis: A retrospective study. Turk. J.
Gastroenterol., 27: 180-6, 2016.
27- LIU P.H., HSU C.Y., HSIA Y., LEE Y.H., CHIOU Y.Y.,
HUANG Y.H., LEE F.Y., et al.: ALBI and PALBI grade
predict survival for HCC across treatment modalities and
BCLC stages in the MELD Era. J. Gastroenterol. Hepatol.,
32: 879-86, 2017.
28- SCAGLIONE S.J., METCALFE L., KLIETHERMES S.,
VASILYEV I., TSANG R., CAINES A., et al.: Early
hospital readmissions and mortality in patients with
decompensated cirrhosis enrolled in a large national health
insurance administrative database. J. Clin. Gastroenterol.,
51: 839-44, 2017.
29- VOLK M.L., TOCCO R.S., BAZICK J., RAKOSKI M.O.
and LOK A.S.: Hospital readmissions among patients
with decompensated cirrhosis. Am. J. Gastroenterol., 107:
247-52, 2012.
30- BIGGINS S.W., KIM W.R., TERRAULT N.A., et al.:
Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology, 130: 1652e1660,
2006.
31- RUF A.E., KREMERS W.K., CHAVEZ L.L., et al.:
Predicts Waiting List Mortality Better than. Vol. 11. 2005:
336e343.
32- ELIZABETH L. GODFREY a, MICHAEL L. KUEHT b,
ABBAS RANA and SAMIR AWAD: MELD-Na (the new
MELD) and peri-operative outcomes in emergency surgery.
The American Journal of Surgery, 216: 407-13, 2018.
Mahmoud H. Allam, et al.
33- OIKONOMOU, IOANNIS GOULIS, PETROS DOUMTSIS, THEODORA TZOUMARI, et al.: ALBI and PALBI
Grades Are Associated with the Outcome of Patients with
Stable Decompensated Cirrhosis. Annals of hepatology,
18 (1): 126-13, 2019.
1255
34- LING Q., HAOJIANG D., RUNZHOU Z., TIAN S.,
WEILIN W., et al.: Predicting short-term survival after
liver transplantation on eight score systems: A national
report from China Liver Transplant Registry. Nature, 7:
42253 | DOI: 10. 103 8/srep42253, 2017.